Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

ClinicalTrials.gov ID: NCT01730040

Public ClinicalTrials.gov record NCT01730040. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind Study of the Efficacy and Safety of Alirocumab Added on to Atorvastatin Versus Ezetimibe Added on to Atorvastatin Versus Atorvastatin Dose Increase Versus Switch to Rosuvastatin in Patients Who Are Not Controlled on Atorvastatin

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).

Study identification

NCT ID
NCT01730040
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
355 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2012
Primary completion
Mar 31, 2014
Completion
Apr 30, 2014
Last update posted
Aug 30, 2015

2012 – 2014

United States locations

U.S. sites
56
U.S. states
27
U.S. cities
56
Facility City State ZIP Site status
Not listed Mobile Alabama
Not listed Chandler Arizona
Not listed Tucson Arizona
Not listed Anaheim California
Not listed Beverly Hills California
Not listed Lakeland Village California
Not listed Newport Beach California
Not listed Northridge California
Not listed Sacramento California
Not listed Walnut Creek California
Not listed Milford Connecticut
Not listed Atlantis Florida
Not listed Boca Raton Florida
Not listed Clearwater Florida
Not listed Jacksonville Florida
Not listed Miami (2 Locations) Florida
Not listed Oviedo Florida
Not listed Pinellas Park Florida
Not listed Port Orange Florida
Not listed Sarasota Florida
Not listed Tampa Florida
Not listed West Palm Beach Florida
Not listed Boise Idaho
Not listed Meridian Idaho
Not listed Chicago Illinois
Not listed Morton Illinois
Not listed Indianapolis Indiana
Not listed Newton Kansas
Not listed Overland Park Kansas
Not listed Wichita Kansas
Not listed Lexington Kentucky
Not listed Louisville Kentucky
Not listed Auburn Maine
Not listed Bethesda Maryland
Not listed Edina Minnesota
Not listed Rochester Minnesota
Not listed Olive Branch Mississippi
Not listed Port Gibson Mississippi
Not listed St Louis Missouri
Not listed Butte Montana
Not listed Las Vegas Nevada
Not listed Williamsville New York
Not listed Winston-Salem North Carolina
Not listed Cleveland Ohio
Not listed Oklahoma City Oklahoma
Not listed Warwick Rhode Island
Not listed Greer South Carolina
Not listed Summerville South Carolina
Not listed Kingsport Tennessee
Not listed Dallas (2 Locations) Texas
Not listed Fort Worth Texas
Not listed Houston Texas
Not listed Bountiful Utah
Not listed Marion Utah
Not listed Salt Lake City Utah
Not listed Renton Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

Recently updated Hypercholesterolemia trials

Other public records listing Hypercholesterolemia. Sorted by last update posted; newest first. Not a recommendation.

All Hypercholesterolemia trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01730040, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 30, 2015 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01730040 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →